403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 10, 2007 at 5:40 PM

Northwest Biotherapeutics gets Swiss jolt

It seems Northwest Biotherapeutics, a local biotech once derided by U.S. capital markets, is benefitting from the Alpine climate.

Shortly after its debut at London Stock Exchange’s stock market for small caps, the company said that Swiss regulatory authorities approved the use of its brain cancer therapeutic vaccine.

The announcement, sent the stock into a wild ride Monday, closing 36 percent higher in London’s Alternative Investment Market. The stock jumped even higher on Tuesday — to an unbelievable 280 pence, up 104 percent.

Not bad for a Bothell-based company that was once kicked out of Nasdaq for running out of cash.

Chief Executive Alton Boynton said:

“Switzerland is an attractive place to begin commercialization, due to its highly respected regulatory oversight, and its growing experience with cellular therapies. Switzerland is also increasingly noted for medical tourism, and is easily accessible for many medical tourists.”

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx